| P2093 | author name string | Peng Zhang | |
| | Yu Li | |
| | Hao Chen | |
| | Luxi Yang | |
| | Zhijian Han | |
| | Yumin Li | |
| | Guodong Sun | |
| | Huijuan Cheng | |
| | Yangbing Li | |
| P2860 | cites work | Global cancer statistics | Q22241238 |
| | Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions | Q26865859 |
| | Functional Restoration of HCV-Specific CD8 T Cells by PD-1 Blockade Is Defined by PD-1 Expression and Compartmentalization | Q27488289 |
| | CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients | Q27692628 |
| | Control of regulatory T cell development by the transcription factor Foxp3 | Q27860489 |
| | The blockade of immune checkpoints in cancer immunotherapy | Q27860852 |
| | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial | Q29547903 |
| | Hepatocellular carcinoma | Q29616359 |
| | Regulatory T cells: mechanisms of differentiation and function | Q29620731 |
| | PD-L1 regulates the development, maintenance, and function of induced regulatory T cells | Q30080038 |
| | Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study | Q33385313 |
| | Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy | Q33933665 |
| | Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer | Q34327051 |
| | Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens | Q34788858 |
| | CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice | Q35528287 |
| | Adaptive immunity suppresses formation and progression of diethylnitrosamine-induced liver cancer | Q35945079 |
| | Spontaneous regression of hepatocellular carcinoma is most often associated with tumour hypoxia or a systemic inflammatory response | Q36120970 |
| | T-cell exhaustion in the tumor microenvironment | Q36347369 |
| | Current management of advanced hepatocellular carcinoma | Q37072518 |
| | PD-1(+) and Foxp3(+) T cell reduction correlates with survival of HCC patients after sorafenib therapy | Q37179971 |
| | Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. | Q37273173 |
| | Management of advanced hepatocellular carcinoma in the era of targeted therapy | Q37361651 |
| | Dynamic behavior and function of Foxp3+ regulatory T cells in tumor bearing host | Q37404916 |
| | Treatment and side effect management of CTLA‐4 antibody therapy in metastatic melanoma | Q37810319 |
| | Liver antigen-presenting cells | Q37810357 |
| | Immunological landscape and immunotherapy of hepatocellular carcinoma | Q38611895 |
| | Immunotherapy in hepatocellular carcinoma: Primed to make a difference? | Q38625948 |
| | CD4+CD25+ regulatory T cells in tumor immunity | Q38781436 |
| | Immunological Microenvironment of Hepatocellular Carcinoma and Its Clinical Implication | Q38986399 |
| | Cancer Statistics, 2017. | Q39038674 |
| | Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma | Q39212591 |
| | Hepatoprotective and immunomodulatory properties of aqueous extract of Curcuma longa in carbon tetra chloride intoxicated Swiss albino mice | Q39335350 |
| | Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial | Q39396355 |
| | Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-infiltrating T cells in Hepatocellular Carcinomas | Q40146079 |
| | Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial | Q40231174 |
| | Myeloid-derived suppressor cells correlate with patient outcomes in hepatic arterial infusion chemotherapy for hepatocellular carcinoma | Q40798040 |
| | A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. | Q42989841 |
| | Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma. | Q45358316 |
| | Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection | Q45368686 |
| | T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer. | Q46973633 |
| | Association Between High-Avidity T-Cell Receptors, Induced by α-Fetoprotein-Derived Peptides, and Anti-Tumor Effects in Patients With Hepatocellular Carcinoma. | Q47439792 |
| | Chemotherapy for hepatocellular carcinoma: current status and future perspectives | Q47775953 |
| | [Nivolumab combined with ipilimumab versus sunitinib monotherapy-SUNNIFORECAST AN 41/16 of the AUO : A phase 2, randomized, open-label study in subjects with previously untreated and advanced (unresectable or metastatic) non-clear cell renal cell ca | Q52838838 |
| | Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. | Q53343023 |
| | [Therapy of untreated local advanced or metastatic renal cell carcinoma. Phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in subjects with previously untreated, local advanced or metastatic r | Q53352740 |
| | Recent developments with immunotherapy for hepatocellular carcinoma | Q56890617 |
| | CTLA-4-blocking immunotherapy with ipilimumab for advanced melanoma | Q56899268 |
| | Targeted and Immune-based Therapies for Hepatocellular Carcinoma | Q57055294 |
| | Nivolumab for the treatment of hepatocellular carcinoma | Q57283779 |
| | Immunotherapy of hepatocellular carcinoma | Q79257932 |
| | Prognostic impact of programmed cell death 1 ligand 1 expression in human leukocyte antigen class I-positive hepatocellular carcinoma after curative hepatectomy | Q87257512 |
| | Treatment of advanced hepatocellular carcinoma: beyond sorafenib | Q88038375 |
| | Nivolumab versus ipilimumab in the treatment of advanced melanoma: a critical appraisal: ORIGINAL ARTICLE: Wolchok JD, Chiarion-Sileni V, Gonzalez R et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 20 | Q88688247 |
| | Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial | Q89012806 |
| | Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort | Q91400248 |
| P433 | issue | 8 | |
| P921 | main subject | immunotherapy | Q1427096 |
| P304 | page(s) | 1536-1545 | |
| P577 | publication date | 2019-08-01 | |
| P1433 | published in | American Journal of Cancer Research | Q17511667 |
| P1476 | title | Trends in the treatment of advanced hepatocellular carcinoma: immune checkpoint blockade immunotherapy and related combination therapies | |
| P478 | volume | 9 | |